- Previous Close
20.60 - Open
20.60 - Bid 20.23 x 700
- Ask 20.41 x 100
- Day's Range
20.10 - 21.07 - 52 Week Range
2.10 - 33.89 - Volume
1,697,499 - Avg. Volume
2,447,254 - Market Cap (intraday)
14.99B - Beta (5Y Monthly) -1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.31 - Earnings Date Apr 29, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.94
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida.
www.summittxinc.comRecent News: SMMT
View MorePerformance Overview: SMMT
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SMMT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SMMT
View MoreValuation Measures
Market Cap
14.99B
Enterprise Value
14.58B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
38.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.30%
Return on Equity (ttm)
-94.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-221.32M
Diluted EPS (ttm)
-0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
412.35M
Total Debt/Equity (mrq)
1.86%
Levered Free Cash Flow (ttm)
-88.94M